EGFR Non-Small Cell Lung Cancer Market Fueled by Targeted Therapies
The EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) market encompasses a range of targeted therapies, companion diagnostics, and supportive care products designed to improve treatment outcomes for patients with EGFR-mutated lung tumors. Key products include first-, second-, and third-generation tyrosine kinase inhibitors (TKIs) that block aberrant EGFR signaling pathways, thereby reducing tumor...
0 Comentários 0 Compartilhamentos 23 Visualizações 0 Anterior